Inactive Instrument

OXiGENE Inc Stock Nasdaq

US6918284042

Biotechnology & Medical Research

End-of-day quote Nasdaq
- ^USD	-

08-13	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâ€™s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	16.2M 13.97M 13.16M 11.99M 22.42M 1.53B 22.58M 156M 60.48M 782M 60.82M 59.49M 2.57B	P/E 2024	-3.13x	P/E 2025	0.13x
Enterprise Value	30.02M 25.9M 24.4M 22.23M 41.55M 2.84B 41.86M 289M 112M 1.45B 113M 110M 4.76B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	56.48%	Yield 2024 *	-	Yield 2025	-

08-13	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
07-22	Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding	CI
07-09	Oncotelic Therapeutics, Inc. announced that it expects to receive $0.71184 million in funding	CI
07-07	Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites	CI
06-29	Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003	CI
06-22	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
06-18	Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026	CI
06-17	Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services	CI
06-17	TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility	CI
06-08	Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development	CI
05-14	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus	CI

08-03	Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th	AQ
07-23	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle Technology Supporting the Ongoing Clinical Development of Sapu003	AQ
07-22	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)	AQ
07-07	Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway	AQ
06-29	Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003	AQ

Manager	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	61	2019-04-21
Amit Bhupendra Shah DFI	Director of Finance/CFO	59	2019-06-30
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	77	2020-01-05

Director	Title	Age	Since
Vuong Trieu CHM	Chairman	61	2019-04-21
Steven King BRD	Director/Board Member	61	2020-05-10
Anthony Maida BRD	Director/Board Member	61	2020-05-10

OXiGENE Inc Stock Nasdaq

Stocks

US6918284042

Biotechnology & Medical Research

Valuation : OXiGENE Inc

Latest news : OXiGENE Inc

Press Releases : OXiGENE Inc

Managers and Directors : OXiGENE Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.03%	-2.05%	+39.28%	+94.60%	68.87B
ARGENX SE	+1.31%	+0.55%	+49.48%	+92.12%	65.29B
INSMED INCORPORATED	-0.02%	+4.30%	-11.77%	+380.13%	27.65B
WUXI BIOLOGICS (CAYMAN) INC.	+2.97%	-0.10%	+41.86%	+14.84%	25.77B
BIONTECH SE	-1.03%	-7.83%	+2.25%	-15.84%	26.08B
GENMAB A/S	+1.01%	+1.38%	+26.48%	-17.50%	20.14B
PHARMAESSENTIA CORPORATION	+3.45%	-14.83%	+225.22%	+389.50%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	-4.55%	-0.36%	+549.41%	15.03B
EXELIXIS, INC.	+1.44%	+7.31%	+60.44%	+166.28%	14.5B
Average	+1.21%	-2.66%	+48.10%	+183.73%	31.15B
Weighted average by Cap.	+1.13%	-2.12%	+42.75%	+142.52%

	2024	2025
Net sales	-	-
Net income	-4.52M -3.9M -3.68M -3.35M -6.26M -427M -6.31M -43.53M -16.89M -218M -16.99M -16.62M -718M	249M 215M 203M 185M 345M 23.55B 348M 2.4B 931M 12.04B 936M 916M 39.55B
Net Debt	13M 11.22M 10.57M 9.63M 17.99M 1.23B 18.13M 125M 48.55M 628M 48.82M 47.76M 2.06B	13.82M 11.93M 11.23M 10.24M 19.13M 1.31B 19.28M 133M 51.62M 668M 51.91M 50.77M 2.19B